OncoMatch/Clinical Trials/NCT05620628
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
Is NCT05620628 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Savolitinib for stomach cancer, adenocarcinoma.
Treatment: Durvalumab · Savolitinib — For patients who failed primary chemotherapy with MET amplification, The efficacy and safety of the chemotherapy are evaluated by using dervalumab and saboritinib in combination.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Gastric Cancer
Biomarker criteria
Required: MET amplification (copy number 4 or higher by local NGS)
MET amplification by local NGS (The NGS result of the implementation agency is defined as copy number 4 or higher, which is the standard for amplification)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy
have progressed during or after 1st or 2nd chemotherapy treatment
Cannot have received: MET inhibitor
Any previous treatment with MET inhibitors
Lab requirements
Blood counts
Haemoglobin ≥9.0 g/dL (within 2 weeks of registration transfusion permitted); ANC ≥ 1.5 x 10^9/L; Platelet count ≥100 x 10^9/L (within 2 weeks of registration transfusion permitted)
Kidney function
Serum creatinine ≤1.5 x institutional ULN; Glomerular filtration rate < 45 mL/min as assessed by standard methodology at the investigating centre
Liver function
ALT and AST ≤2.5 x ULN with TBL≤ 1x ULN OR TBL >1ULN-≤1.5x ULN with ALT and AST ≤ 1x ULN
Cardiac function
Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from 3 electrograms (ECGs) using Friderecia's correction
Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below: * Haemoglobin ≥9.0 g/dL (within 2 weeks of registration transfusion permitted) * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelet count ≥100 x 109/L (within 2 weeks of registration transfusion permitted) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x the upper limit of normal (ULN) with TBL≤ 1x ULN OR TBL >1ULN-≤1.5x ULN with ALT and AST ≤ 1x ULN * Serum creatinine ≤1.5 x institutional ULN * Glomerular filtration rate < 45 mL/min as assessed by standard methodology at the investigating centre
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05620628 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MET inhibitor disqualifies patients from enrollment.
Does this trial require MET?
Yes, MET amplification is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages